• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

68Ga-FAPI PET/CT 显像在胰腺癌多处肌肉转移中的应用。

68Ga-FAPI PET/CT Imaging of Multiple Muscle Metastases of Pancreatic Cancer.

机构信息

From the Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University; Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province; and Academician (Expert) Workstation of Sichuan Province, Luzhou, Sichuan, China.

出版信息

Clin Nucl Med. 2022 Jan 1;47(1):73-75. doi: 10.1097/RLU.0000000000003888.

DOI:10.1097/RLU.0000000000003888
PMID:34874351
Abstract

A 67-year-old man presented with generalized muscle pain for 2 months. A potential malignancy was suspected. The patient was subsequently enrolled in the clinical trial of 68Ga-FAPI. Increased activity of FAPI and FDG was observed in muscle lesions. Moreover, 68Ga-FAPI PET/CT showed intense FAPI uptake in the pancreas. Finally, pancreas and left iliopsoas muscle biopsies confirmed the diagnosis of pancreatic cancer with multiple muscle metastases.

摘要

一位 67 岁男性因全身肌肉疼痛就诊,病程 2 个月。疑似恶性肿瘤。患者随后参加了 68Ga-FAPI 的临床试验。在肌肉病变处观察到 FAPI 和 FDG 的活性增加。此外,68Ga-FAPI PET/CT 显示胰腺摄取 FAPI 明显增加。最终,胰腺和左侧髂腰肌活检证实了胰腺癌伴多发肌肉转移的诊断。

相似文献

1
68Ga-FAPI PET/CT Imaging of Multiple Muscle Metastases of Pancreatic Cancer.68Ga-FAPI PET/CT 显像在胰腺癌多处肌肉转移中的应用。
Clin Nucl Med. 2022 Jan 1;47(1):73-75. doi: 10.1097/RLU.0000000000003888.
2
Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the Imaging of Pancreatic Cancer With Liver Metastases.68Ga-FAPI 与 18F-FDG PET/CT 对胰腺癌细胞肝转移的影像学比较。
Clin Nucl Med. 2021 Jul 1;46(7):589-591. doi: 10.1097/RLU.0000000000003561.
3
Intense FAPI Uptake in Inflammation May Mask the Tumor Activity of Pancreatic Cancer in 68Ga-FAPI PET/CT.68Ga-FAPI PET/CT 中炎症部位 FAPI 摄取高可能掩盖胰腺癌的肿瘤活性。
Clin Nucl Med. 2020 Apr;45(4):310-311. doi: 10.1097/RLU.0000000000002914.
4
Comparison of 18F-FDG, 68Ga-FAPI, and 68Ga-DOTATATE PET/CT in a Patient With Pancreatic Neuroendocrine Tumor.18F-FDG、68Ga-FAPI 和 68Ga-DOTATATE PET/CT 在胰腺神经内分泌肿瘤患者中的比较。
Clin Nucl Med. 2021 Sep 1;46(9):764-765. doi: 10.1097/RLU.0000000000003763.
5
Positron emission tomography and computed tomography with [Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer.使用[镓]镓-成纤维细胞活化蛋白抑制剂的正电子发射断层扫描和计算机断层扫描可改善胰腺癌患者的肿瘤检测和分期。
Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1322-1337. doi: 10.1007/s00259-021-05576-w. Epub 2021 Oct 15.
6
Tumor Imaging With 68Ga-DOTA-FAPI-04 PET/CT: Comparison With 18F-FDG PET/CT in 22 Different Cancer Types.68Ga-DOTA-FAPI-04 PET/CT 肿瘤成像:与 18F-FDG PET/CT 在 22 种不同癌症类型中的比较。
Clin Nucl Med. 2022 Apr 1;47(4):e333-e339. doi: 10.1097/RLU.0000000000004073.
7
68Ga-FAPI PET/CT Detected Non-FDG-Avid Gastric Stromal Tumor.68Ga-FAPI PET/CT 检测到非 FDG 摄取的胃间质瘤。
Clin Nucl Med. 2022 Mar 1;47(3):226-227. doi: 10.1097/RLU.0000000000003856.
8
Comparison of the diagnostic efficacy of  Ga-FAPI-04 PET/MR and F-FDG PET/CT in patients with pancreatic cancer.Ga-FAPI-04 PET/MR 与 F-FDG PET/CT 诊断胰腺癌的效能比较。
Eur J Nucl Med Mol Imaging. 2022 Jul;49(8):2877-2888. doi: 10.1007/s00259-022-05729-5. Epub 2022 Mar 4.
9
Intense 68Ga-FAPI Uptake in a Patient With Myositis Ossificans: Mimicking Bone Malignancy.患者骨化性肌炎出现强烈 68Ga-FAPI 摄取:类似骨恶性肿瘤。
Clin Nucl Med. 2022 Jul 1;47(7):638-639. doi: 10.1097/RLU.0000000000004213. Epub 2022 Apr 15.
10
Comparison of 18F-FDG and 68Ga-FAPI PET/CT in Gastric Kaposi Sarcoma.18F-FDG与68Ga-FAPI PET/CT在胃卡波西肉瘤中的比较
Clin Nucl Med. 2022 Sep 1;47(9):e596-e599. doi: 10.1097/RLU.0000000000004172. Epub 2022 Apr 5.

引用本文的文献

1
F-FAPI-04 Outperforms F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma.F-FAPI-04 在胰腺腺癌患者的临床评估中优于 F-FDG PET/CT。
J Nucl Med. 2024 Feb 1;65(2):206-212. doi: 10.2967/jnumed.123.266283.